ID26334A - Morfolinol yang aktif secara farmasi - Google Patents

Morfolinol yang aktif secara farmasi

Info

Publication number: ID26334A
Authority: ID; Indonesia
Prior art keywords: morpholinol; activate; pharmaceutical; pharmaceutical activate; activate morpholinol
Prior art date: 1998-01-21

Application number

IDW20001597A

Other languages

English (en)

Indonesian (id)

Inventor

Phillip Frederick Morgan

David Lee Musso

John Joseph Partridge

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-20

Publication date

2000-12-14

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

1999-01-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-12-14 Publication of ID26334A publication Critical patent/ID26334A/id

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IDW20001597A 1998-01-21 1999-01-20 Morfolinol yang aktif secara farmasi ID26334A (id)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22

Publications (1)

Publication Number	Publication Date
ID26334A true ID26334A (id)	2000-12-14

Family

ID=26312986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW20001597A ID26334A (id)	1998-01-21	1999-01-20	Morfolinol yang aktif secara farmasi

Country Status (30)

Country	Link
US (2)	US6274579B1 (fr)
EP (2)	EP1047428B1 (fr)
JP (1)	JP2002501025A (fr)
KR (1)	KR100568063B1 (fr)
CN (2)	CN1203858C (fr)
AP (1)	AP1229A (fr)
AT (1)	ATE365042T1 (fr)
AU (1)	AU755536B2 (fr)
BR (1)	BR9907203A (fr)
CA (1)	CA2318268A1 (fr)
CY (1)	CY1106828T1 (fr)
DE (1)	DE69936335T2 (fr)
DK (1)	DK1047428T3 (fr)
EA (1)	EA002410B1 (fr)
EE (1)	EE04452B1 (fr)
ES (1)	ES2288012T3 (fr)
HR (2)	HRP20051024A2 (fr)
HU (1)	HUP0100900A3 (fr)
ID (1)	ID26334A (fr)
IL (2)	IL161942A0 (fr)
IS (1)	IS2494B (fr)
NO (2)	NO326878B1 (fr)
NZ (3)	NZ520349A (fr)
PL (1)	PL193622B1 (fr)
PT (1)	PT1047428E (fr)
SG (1)	SG115489A1 (fr)
SK (1)	SK10912000A3 (fr)
TR (1)	TR200002126T2 (fr)
WO (1)	WO1999037305A1 (fr)
YU (1)	YU67102A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
CA2318921A1 (fr) *	1998-01-29	1999-08-05	John R. Mccullough	Usages pharmacologiques de (+)-bupropion optiquement pur
WO1999038504A1 (fr)	1998-01-29	1999-08-05	Sepracor Inc.	Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
EP1220673A2 (fr) *	1999-10-13	2002-07-10	Glaxo Group Limited	Methode destinee au traitement de l'obesite
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (fr) *	2000-12-21	2008-10-21	Brasscorp Limited	Methode pour produire une source de lumiere ultraviolette ou proche de l'ultraviolet destinee a une inspection ou un essai non destructif
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
WO2003097046A1 (fr) *	2002-05-17	2003-11-27	Duke University	Procede de traitement de l'obesite
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
DE60324685D1 (de) *	2002-08-23	2008-12-24	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
DE602004012403T2 (de) *	2003-04-29	2009-03-19	Orexigen Therapeutics, Inc., La Jolla	Zusammensetzungen zur beeinflussung des gewichtsverlusts
JP2007509855A (ja) *	2003-10-27	2007-04-19	スミスクラインビーチャムコーポレーション	（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するためのジアステレオマー動的速度論分割プロセス
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
BRPI0506829A (pt) *	2004-01-13	2007-05-29	Univ Duke	composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20050277579A1 (en) *	2004-05-03	2005-12-15	Ranga Krishnan	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
PL2135603T3 (pl)	2005-11-22	2013-09-30	Orexigen Therapeutics Inc	Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007079470A2 (fr)	2006-01-03	2007-07-12	Algebra, Inc.	Composes therapeutiques amine-arylsulfonamide conjugues
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP2089005B1 (fr)	2006-11-09	2010-03-17	Orexigen Therapeutics, Inc.	Formulations pharmaceutiques en couches comprenant une couche intermédiaire à dissolution rapide
TW200829235A (en)	2006-11-09	2008-07-16	Orexigen Therapeutics Inc	Methods for administering weight loss medications
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
EP2419400A1 (fr)	2009-04-15	2012-02-22	Research Triangle Institute	Inhibiteurs de la recapture des monoamines
JP6196041B2 (ja)	2010-01-11	2017-09-13	オレキシジェン・セラピューティクス・インコーポレーテッド	大うつ病を有する患者において減量療法を提供する方法
CA2800219C (fr) *	2010-05-21	2019-03-12	Research Triangle Institute	Analogues d'hydroxybupropion pour le traitement de la pharmacodependance
JP2013526583A (ja)	2010-05-21	2013-06-24	リサーチ・トライアングル・インスティチュート	フェニルモルホリンおよびその類似体
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
CA2875056C (fr)	2012-06-06	2024-03-26	Orexigen Therapeutics, Inc.	Methodes de traitement de la surcharge ponderale et de l'obesite
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/fr not_active Expired - Lifetime
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/fr not_active Ceased
- 1999-01-20 EP EP07110283A patent/EP1829544A1/fr not_active Withdrawn
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/fr not_active Abandoned
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2002501025A (ja)	2002-01-15
AP2000001869A0 (en)	2000-09-30
DK1047428T3 (da)	2007-10-08
CY1106828T1 (el)	2012-05-23
EE200000438A (et)	2001-12-17
CN1255389C (zh)	2006-05-10
AU2328099A (en)	1999-08-09
CN1294513A (zh)	2001-05-09
CN1528753A (zh)	2004-09-15
WO1999037305A1 (fr)	1999-07-29
HRP20000494A2 (en)	2000-12-31
IS5568A (is)	2000-07-20
BR9907203A (pt)	2000-10-17
PL342012A1 (en)	2001-05-07
CA2318268A1 (fr)	1999-07-29
NO20003721D0 (no)	2000-07-20
ES2288012T3 (es)	2007-12-16
EP1047428A4 (fr)	2001-12-19
HUP0100900A2 (hu)	2002-05-29
AP1229A (en)	2003-12-04
SG115489A1 (en)	2005-10-28
IL137346A0 (en)	2001-07-24
DE69936335T2 (de)	2008-02-28
HRP20000494B1 (en)	2009-02-28
IS2494B (is)	2009-02-15
PT1047428E (pt)	2007-09-07
US6274579B1 (en)	2001-08-14
CN1203858C (zh)	2005-06-01
EP1829544A1 (fr)	2007-09-05
KR100568063B1 (ko)	2006-04-07
HUP0100900A3 (en)	2002-08-28
SK10912000A3 (sk)	2001-04-09
KR20010034285A (ko)	2001-04-25
NO20083529L (no)	2000-09-19
IL161942A0 (en)	2005-11-20
NO326878B1 (no)	2009-03-09
HRP20051024A2 (hr)	2006-04-30
PL193622B1 (pl)	2007-02-28
YU67102A (sh)	2004-12-31
EP1047428B1 (fr)	2007-06-20
ATE365042T1 (de)	2007-07-15
DE69936335D1 (de)	2007-08-02
AU755536B2 (en)	2002-12-12
EA002410B1 (ru)	2002-04-25
TR200002126T2 (tr)	2000-12-21
NO20003721L (no)	2000-09-19
US6391875B2 (en)	2002-05-21
EA200000691A1 (ru)	2001-04-23
NZ520349A (en)	2004-02-27
NZ505809A (en)	2002-09-27
NZ529316A (en)	2004-05-28
EP1047428A1 (fr)	2000-11-02
EE04452B1 (et)	2005-04-15
US20020019396A1 (en)	2002-02-14

Publication	Publication Date	Title
ID26334A (id)	2000-12-14	Morfolinol yang aktif secara farmasi
ID28110A (id)	2001-05-03	Surfaktan alkilbenzenasulfonat yang disempurnakan
ID27841A (id)	2001-04-26	Turunan-turunan biaril terapeutik
IS5425A (is)	2000-03-31	Læknislyf
NO992339L (no)	1999-11-16	Farmasöytiske formuleringer
DE69924365D1 (de)	2005-04-28	Massagegerät
ID26330A (id)	2000-12-14	Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
ID27415A (id)	2001-04-05	Komposisi farmaseutik
ID22939A (id)	1999-12-16	Formulasi-formulasi farmasi yang mengandung vorikonozal
NO992692D0 (no)	1999-06-03	Nefadozon doseringsform
ID29262A (id)	2001-08-16	Komposisi farmasi
DK1466615T3 (da)	2009-08-31	Farmaceutisk præparat
DE69921571D1 (de)	2004-12-09	Massagegerät
ID23735A (id)	2000-05-11	Tablet trovafloksasin mesilat
DE69908262D1 (de)	2003-07-03	Sprühbehälter
ID27201A (id)	2001-03-08	Komposisi farmasi
EP1061784A4 (fr)	2005-05-04	Unite radio-electronique
NO994619L (no)	1999-11-23	Farmasöytiske blandinger
ID30032A (id)	2001-11-01	Formulasi farmasi
EP1074250A4 (fr)	2002-02-06	Comprimes drageifies
FR2782671B3 (fr)	2000-07-21	Livre
NO20003141D0 (no)	2000-06-16	Farmasøytiske blandinger
DK1051156T3 (da)	2003-06-23	Farmaceutiske præparater
DE59904743D1 (de)	2003-04-30	Exzenteranordnung
ID27593A (id)	2001-04-12	Tetrahidronaftilidinil-karboksamida yang mempunyai aktivitas anti-konvulsan